Hereditary motor and sensory neuropathy
Methodology & AI Transparency ⓘ
Hereditary motor and sensory neuropathy Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code G60.0 in Brain & Neurology, Hereditary motor and sensory neuropathy requires sensorimotor neurologic examination [Hereditary motor and sensory neuropathy G60.0] so specialists can calibrate treatment intensity against Serum Vitamin B12 in Hereditary motor and sensory neuropathy (G60.0: & Methylmalonic Acid) benchmarks.
- 2 Real-world patient consensus: Clinical coding for Hereditary motor and sensory neuropathy uses ICD-10 G60.0 across Brain & Neurology specialty care.
- 3 Typical cash cost range: Clinicians assessing Hereditary motor and sensory neuropathy focus on blood-brain barrier neuroinflammation [Hereditary motor and sensory neuropathy G60.0] and targeted history.
- 4 Top reported side effects / signs: Longitudinal Hereditary motor and sensory neuropathy monitoring tracks Serum Vitamin B12 in Hereditary motor and sensory neuropathy (G60.0: & Methylmalonic Acid) toward B12 > 500 pg/mL; MMA < 240 nmol/L (G60.0).
Ask our AI Specialists anything about Hereditary motor and sensory neuropathy
What Is Hereditary motor and sensory neuropathy?
Cataloged under federal diagnostic code G60.0 in Brain & Neurology, Hereditary motor and sensory neuropathy requires sensorimotor neurologic examination [Hereditary motor and sensory neuropathy G60.0] so specialists can calibrate treatment intensity against Serum Vitamin B12 in Hereditary motor and sensory neuropathy (G60.0: & Methylmalonic Acid) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
In Hereditary motor and sensory neuropathy (G60.0), physiological disruption stems from blood-brain barrier neuroinflammation [Hereditary motor and sensory neuropathy G60.0], informing Neurology, Stroke & Movement Disorders protocols that track Carotid Duplex / in Hereditary motor and sensory neuropathy (G60.0: Cerebral Perfusion) (No hemodynamically significant stenosis (G60.0)).
Common Symptoms & Clinical Signs
- • Presentation of Hereditary motor and sensory neuropathy (G60.0): muscle stiffness, spasticity, in Hereditary motor and sensory neuropathy (G60.0: or fatigable neuromuscular)
- • Secondary Hereditary motor and sensory neuropathy clinical sign: focal motor weakness, in Hereditary motor and sensory neuropathy (G60.0: resting or action)
- • Symptom flares in Hereditary motor and sensory neuropathy correlating with Serum Vitamin B12 in Hereditary motor and sensory neuropathy (G60.0: & Methylmalonic Acid) deviation outside B12 > 500 pg/mL; MMA < 240 nmol/L (G60.0)
- • Functional brain & neurology impact requiring sensorimotor neurologic examination [Hereditary motor and sensory neuropathy G60.0] evaluation (G60.0)
Hereditary motor and sensory neuropathy Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G60.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Neurology, Stroke & Movement Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: Serum Vitamin B12 in Hereditary motor and sensory neuropathy (G60.0: & Methylmalonic Acid) | B12 > 500 pg/mL; MMA < 240 nmol/L (G60.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Carotid Duplex / in Hereditary motor and sensory neuropathy (G60.0: Cerebral Perfusion) | No hemodynamically significant stenosis (G60.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HbA1c & Blood in Hereditary motor and sensory neuropathy (G60.0: Pressure Neuro-Targets) | BP < 120/75 mmHg; HbA1c < 5.7% (G60.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Hereditary motor and sensory neuropathy
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Garadacimab Andembry • RxCUI 2717175 | FDA Prescription Therapeutic Agent | 86% | $3.5700 | $ 153.09 /mo |
| Icatibant Sajazir • RxCUI 1148141 | Bradykinin B2 Receptor Antagonist | 76% | $1.1800 | $ 56.29 /mo |
| Entacapone Comtan • RxCUI 317094 | Catechol-O-Methyltransferase Inhibitor | 75% | $0.3246 | $ 8.45 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hereditary motor and sensory neuropathy)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety experience with continued exposure to ofatumumab in patients with: What a 1,650-Participant Study Found In patients with up to 3.5 years' exposure, ofatumumab was well tolerated, with no new safety risks identified. Multiple sclerosis (Houndmills, Basingstoke, England) • 2022-09-15 • Phase III Randomized Trial | N = 1,650 | 90/100 | PMID 35229668 ↗ |
| Can This Approach Help? Inside the Latest Research on Berotralstat and Health-Related Quality of Life in Hereditary Angioedema: Pooled Berotralstat significantly improved HRQoL versus placebo through 24 weeks and showed long-term beneficial effects through 96 weeks. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology • 2026-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42036875 ↗ |
| Can This Approach Help? Inside the Latest Research on Switching from inotersen to eplontersen in patients with hereditary Switching from inotersen to eplontersen further reduced serum TTR, halted disease progression, stabilized QoL, restored platelet count, and improved tolerability, without deterioration in nutritional status. Journal of neurology • 2024-10-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39138650 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of Eplontersen on Cardiac Structure and Function in Patients With Eplontersen was associated with stable or improved measures of cardiac structure and function vs historical placebo in patients with ATTRv polyneuropathy and cardiomyopathy. Journal of cardiac failure • 2024-08-15 • Phase III Randomized Trial | N = 144 | 88/100 | PMID 38065307 ↗ |
| Can This Approach Help? Inside the Latest Research on Proton pump inhibition for secondary hemochromatosis in hereditary anemia: a In summary, esomeprazole resulted in a significant reduction in liver iron content when compared to placebo in a heterogeneous group of patients with non-transfusion-dependent hereditary anemias. American journal of hematology • 2022-07-15 • Phase III Randomized Trial | N = 30 | 88/100 | PMID 35472008 ↗ |
Hereditary motor and sensory neuropathy Patient Community & “People Like Me” Threads
Filter Hereditary motor and sensory neuropathy community threads and patient logs by age, biological sex, dosage, and treatment duration.